Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A mechanistically sound study combining genetic and pharmacological approaches in mouse and human models, demonstrating PRMT7 inhibition enhances CD8+ T cell function, but limited by single tumor model and lack of phase-controlled clinical trial.
This is a mechanistic discovery study identifying a novel epigenetic element class (Methylation Mesa) and demonstrating proof-of-concept that targeted demethylation drives gene activation in cell models, but lacks clinical endpoint data or confirmatory independent validation.
Translational study combining transcriptomic analysis, tissue immunofluorescence, and in vitro/in vivo cell models to characterize a signaling axis; lacks clinical trial evidence of BNCT response prediction or prognostic validation.
In vitro mechanistic study in cancer cell lines demonstrating that DNMT1 inhibition modulates EMT markers and reduces invasiveness in docetaxel-resistant prostate cancer, but lacks in vivo validation, clinical endpoints, or human data.
Retrospective cohort study with appropriate statistical methods and hard clinical endpoints (overall and disease-free survival) showing independent associations between m6A genetic variants and poor prognosis after gastrectomy, but limited by single-centre design, retrospective conduct, and lack of external validation.
In vitro mechanistic study in cell lines and engineered cells examining epigenetic mechanisms in MPNSTs; demonstrates proof-of-concept but lacks in vivo validation or clinical data.